THE EFFECT OF ANTI-PD-1 THERAPY ON MEDIAN OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL IN GLIOBLASTOMA MULTIFORME PATIENTS WITH CERTAIN TUMOR MARKERS

被引：1
|
作者：
Paracha, Awais [1 ]
Campian, Jian [2 ]
机构：
[1] St Louis Univ, Sch Med, St Louis, MO USA
[2] Washington Univ, St Louis, MO 63110 USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷
关键词：
D O I：
10.1136/jitc-2020-SITC2020.0214
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
214
引用
收藏
页码：A128 / A128
页数：1
相关论文
共 50 条
  • [41] Circulating tumor cells are a reliable predictor of progression free survival and overall survival during therapy of patients with metastatic breast cancer
    Hayes, DF
    Miller, MC
    Cristofanilli, M
    Ellis, MJ
    Stopek, A
    Allard, WJ
    Matera, J
    Doyle, GV
    Terstappen, LWWM
    Budd, GT
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S225 - S225
  • [42] Prognostic markers for progression free survival (PFS) to anti PD-1 therapies in metastatic melanoma
    Swami, Umang
    Monga, Varun
    Knutson, Tina
    Bossler, Aaron D.
    Zakharia, Yousef
    Milhem, Mohammed M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] IMPACT ON REMOTE FUNCTIONAL AREAS DUE TO TUMOR MASS EFFECT IS PROGNOSTIC OF OVERALL SURVIVAL IN GLIOBLASTOMA MULTIFORME
    Mitra, Jhimli
    Nayate, Ameya
    Madabhushi, Anant
    Tiwari, Pallavi
    NEURO-ONCOLOGY, 2016, 18 : 135 - 135
  • [44] Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine
    D. H. Heiland
    W. Masalha
    P. Franco
    M. R. Machein
    A. Weyerbrock
    Journal of Neuro-Oncology, 2016, 126 : 567 - 575
  • [45] Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine
    Heiland, D. H.
    Masalha, W.
    Franco, P.
    Machein, M. R.
    Weyerbrock, A.
    JOURNAL OF NEURO-ONCOLOGY, 2016, 126 (03) : 567 - 575
  • [46] The use of Anti-PD1 Therapy in Melanoma Patients with Known Brain Metastases: Survival, Durable Intracranial Progression Free Survival and Radionecrosis
    Rahman, R.
    Niemierko, A.
    Cortes, A.
    Oh, K. S.
    Flaherty, K. T.
    Lawrence, D. P.
    Sullivan, R. J.
    Shih, H. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E275 - E275
  • [47] Association of Progression-Free Survival With Overall Survival in Patients With Neuroendocrine Tumor Treated With Somatostatin Analogs
    Ter-Minassian, Monica
    Brooks, Nichole V.
    Brais, Lauren K.
    Chan, Jennifer A.
    Christiani, David C.
    Lin, Xihong
    Gabriel, Sylvie
    Dinet, Jerome
    Kulke, Matthew H.
    PANCREAS, 2016, 45 (03) : 483 - 483
  • [48] IS SURGERY AT PROGRESSION A PROGNOSTIC MARKER FOR IMPROVED 6-MONTH PROGRESSION-FREE SURVIVAL OR OVERALL SURVIVAL FOR PATIENTS WITH RECURRENT GLIOBLASTOMA?
    Clarke, J. L.
    Ennis, Michele M.
    Lamborn, Kathleen R.
    Prados, Michael D.
    NEURO-ONCOLOGY, 2010, 12 : 69 - 69
  • [49] Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?
    Clarke, Jennifer L.
    Ennis, Michele M.
    Yung, W. K. Alfred
    Chang, Susan M.
    Wen, Patrick Y.
    Cloughesy, Timothy F.
    DeAngelis, Lisa M.
    Robins, H. Ian
    Lieberman, Frank S.
    Fine, Howard A.
    Abrey, Lauren
    Gilbert, Mark R.
    Mehta, Minesh
    Kuhn, John G.
    Aldape, Kenneth D.
    Lamborn, Kathleen R.
    Prados, Michael D.
    NEURO-ONCOLOGY, 2011, 13 (10) : 1118 - 1124
  • [50] Letter to the editor: Dexamethasone and overall survival and progression free survival in patients with newly diagnosed glioblastoma: a meta-analysis
    Peter G. Zaki
    Sanjeev Herr
    Matthew J. Shepard
    Journal of Neuro-Oncology, 2024, 167 : 363 - 364
12345